Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion to boost its oncology pipeline, the company said Wednesday.
This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to b... [3024 chars]